A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks

• Phase: Phase 3

Details

• Lead Sponsor: Novartis

Criteria

Inclusion Criteria:

• Male and female outpatients 18 years of age and older

• Patients who are eligible and able to participate in the study

Exclusion Criteria:

• Severe hypertension

• History or evidence of a secondary form of hypertension

• History of hypertensive encephalopathy or cerebrovascular accident.

Other protocol-defined inclusion/exclusion criteria may apply